Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes&lt;SUBTITLE&gt;The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial&lt;/SUBTITLE&gt;

Vogel, Victor G.; Costantino, Joseph P.; Wickerham, D. Lawrence; Cronin, Walter M.; Cecchini, Reena S.; Atkins, James N.; Bevers, Therese B.; Fehrenbacher, Louis; Wade, James L.; Margolese, Richard G.; Lippman, Scott M.; Runowicz, Carolyn D.; Ganz, Patricia A.; Reis, Steven E.; Ford, Leslie G.; Jordan, V. Craig; Wolmark, Norman

doi:10.1001/jama.295.23.joc60074

Cited by 1,546 publications

(842 citation statements)

References 44 publications

Supporting

Mentioning

799

Contrasting

Unclassified

Order By: Relevance

“…Vogel et al [35] observed a significant reduction of incidence of contralateral primary breast cancer among women receiving adjuvant hormonal therapy. Adjuvant hormonal therapy also reported to reduce the incidence of BBC by 40% in both ER positive and ER negative patients [36].…”

Section: Discussionmentioning

confidence: 98%

Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics

Kheirelseid

Jumustafa

Miller

et al. 2010

Breast Cancer Res Treat

141

133

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 98%

Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics

Kheirelseid

Jumustafa

Miller

et al. 2010

Breast Cancer Res Treat

141

133

View full text Add to dashboard Cite

show abstract

“…The most important side effects reported in patients undergoing long-term tamoxifen treatment consist of visual impairment, cataracts, 61 and risk of thromboembolic events. 62,63 Tamoxifen has weak estrogenic properties that can induce endometrial cell proliferation and, consequently, endometrial cancer. 64 In addition, tamoxifen seems to increase the risk of radiation-induced lung and skin fibrosis.…”

Section: Discussionmentioning

confidence: 99%

Antifibrotic Effect of Tamoxifen in a Model of Progressive Renal Disease

Dellê

Rocha

Cavaglieri

et al. 2012

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Tamoxifen, a selective estrogen receptor modulator, has antifibrotic properties; however, whether it can attenuate renal fibrosis is unknown. In this study, we tested the effects of tamoxifen in a model of hypertensive nephrosclerosis (chronic inhibition of nitric oxide synthesis with L-NAME). After 30 days, treated rats had significantly lower levels of albuminuria as well as lower histologic scores for glomerulosclerosis and interstitial fibrosis than untreated controls. Tamoxifen was renoprotective despite having no effect on the sustained, severe hypertension induced by L-NAME. Tamoxifen prevented the accumulation of extracellular matrix by decreasing the expression of collagen I, collagen III, and fibronectin mRNA and protein. These renoprotective effects associated with inhibition of TGF-b1 and plasminogen activator inhibitor-1, and with a significant reduction in a-smooth muscle actin-positive cells in the renal interstitium. Furthermore, tamoxifen abrogated IL-1b-and angiotensin-II-induced proliferation of fibroblasts from both kidney explants and from the NRK-49F cell line. Tamoxifen also inhibited the expression of extracellular matrix components and the production and release of TGF-b1 into the supernatant of these cells. In summary, tamoxifen exhibits antifibrotic effects in the L-NAME model of hypertensive nephrosclerosis, likely through the inhibition of TGF-b1, suggesting that it may have therapeutic use in CKD treatment.

show abstract

“…Raloxifene and tamoxifen have been shown to cut down the risk of estrogenreceptor positive breast cancers by as much as 50% (Vogel et al 2006). Tamoxifen, a selective estrogen receptor modulator, has demonstrated benefit when used alone as well as in combination with chemotherapy to treat advanced breast cancer.…”

Section: Estrogen Signalingmentioning

confidence: 99%